Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VK3019 Single Ascending Dose Study in Overweight and Obese Adults
NCT07846033Phase 1Recruiting
- Sponsor
- Viking Therapeutics
- Start
- Jul 2026
- Primary completion
- Oct 2026
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VK3019 in obesity (7 arms), sponsored by Viking Therapeutics. Primary endpoint: Safety and Tolerability at 36 days. Started Jul 2026; status: recruiting.
02
Drugs
VK3019
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07846033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07846033.